Dauricine, a bisbenzylisoquinoline alkaloid derived from Menispermum dauricum, exhibits anti-inflammatory properties. It hampers cell proliferation and invasion and prompts apoptosis by inhibiting NF-κB activation in a dose- and time-dependent manner in colon cancer[1].
体内研究
Dauricine, when administered subcutaneously at 40 mg/kg every two days for nine days, inhibits the growth of colonic tumors in a HCT116 xenograft mouse model[1].
Dauricine, given intraperitoneally at 1 or 10 mg/kg, mitigates cognitive impairment, diminishes Aβ accumulation, and curtails Tau hyperphosphorylation in 3xTg-Alzheimer's Disease mice[2].
体外研究
Dauricine, at concentrations ranging from 0 to 20 μM over a period of 8 days, suppresses the growth of HCT116, HCT8, SW620, and SW480 cells[1].
Dauricine, at concentrations from 0 to 20 μM, induces G1 phase cell-cycle arrest in HCT116 cells after 12 and 24 hours of treatment[1].
Dauricine, in concentrations ranging from 0 to 20 μM over a period of 36 hours, induces apoptosis in HCT116 cells and inhibits their invasion[1].
Dauricine, administered at 0-20 μM for 6 hours, suppresses the activation of the NF-κB signaling pathway in HCT116 cells[1].
Dauricine (1 and 2 μg/mL, 24 h) inhibits glucose glycolysis and increased oxidative phosphorylation in HepG2 and Huh-7 cells[3].
Dauricine (2 μg/mL, 48 h) increases the sensitivities of HCC cell lines to both Cisplatin and Sorafenib[3].
搜索
